Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA’s Biologics Center May Be Busier After Coronavirus Subsides, Director Says

Jun 12 2020

• By Derrick Gingery

BIO speakers dog comes into meeting — A dog made a surprise appearance while the shaggy director of CBER was speaking during a Biotechnology Innovation Organization International Convention session. • Source: Screenshot

Related Content

Patient-Reported Data In COVID-Impacted Trials: US FDA Cautions Against Missing Data, Potential Bias

Jun 07 2020

BIO 2020 Notebook: Conversations On Rebates, Racism, And Remote Working

Jun 12 2020

BIO 2020 Notebook: FDA's Hahn On COVID-19 Lessons To Be Learned; NIH's Fauci On Health Care Disparities; Pfizer's Young On Forgoing Gov't Vaccine Funds

Jun 11 2020

US FDA’s Gene Therapy Work Feeling The Effects Of Pandemic Response

Jun 10 2020

US FDA Not Missing Assessment Goals, But Guidance Reminds That It’s Possible

Jun 01 2020

Seven Days In March: NDA-BLA and ANDA Approval Output Diverged As Coronavirus Teleworking Began

Apr 30 2020

For COVID-Impacted Trials, Investigators Should Practice Remote Assessments Beforehand, US FDA Says

Apr 20 2020

Additional Topics

United States Coronavirus COVID-19 Biologics Gene Therapy Regulation FDA Review Pathway Leadership Regenerative Medicine BioPharmaceutical

More from Cell & Gene Therapies

More from Advanced Technologies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window